Preparation
Bislor Tablet: Each film coated tablet contains Bilastine INN 20 mg.
Indication
Allergic Rhinitis: Bilastine is indicated for the symptomatic relief of allergic rhinitis.
Allergic Rhino conjunctivitis: Bilastine is indicated for the relief of the symptoms associated with allergic rhino conjunctivitis.
Urticaria: Bilastine is indicated for the relief of the symptoms associated with urticaria (e.g. pruritus).
Contraindication
Bilastine is contraindicated in patients with: Hypersensitivity to Bilastine or to any ingredient in the formulation or component of the tablet.
Dosage & Administration
Adults & adolescents (12 years of age and over): 20 mg tablet once daily for symptomatic relief of allergic rhinitis, urticaria and allergic rhinoconjunctivitis. The maximum recommended daily dose is 20 mg Bilastine (1 tablet) and should not be exceeded. If a dose is missed, the next scheduled dose should be taken. An extra dose should not be taken.
Side Effect
The most common side effects of Bilastine include: headache, dizziness and fatigue.
Precaution
Bilastine should be taken cautiously in case of moderate to severe renal impairment.
Drug Interaction
Interaction with Ketoconazole or Erythromycin: Concomitant intake of Bilastine and Ketoconazole or Erythromycin increased Bilastine AUC 2-fold and Cmax 2-3 fold.
Interaction with Diltiazem: Concomitant intake of Bilastine 20 mg and Diltiazem 60 mg increased Cmax of Bilastine by 50%. It does not appear to affect the safety profile of Bilastine.
Interaction with Lorazepam: Concomitant intake of Bilastine 20 mg and Lorazepam 3 mg for 8 days did not potentiate the depressant CNS effects of Lorazepam.
Presentation
Bislor Tablet: Each box contains 3X10’s tablets in Alu-Alu blister pack.
Use Children
The safety and efficacy of Bilastine in children under 12 years of age have not been established.
Use Pregnancy Lactation
There are no adequate and well-controlled studies in pregnant women. Until such data become available, Bilastine should be avoided during pregnancy, unless advised otherwise by a physician.
Overdosage
Information regarding acute overdose of Bilastine is retrieved from the experience of clinical trials conducted during the development and the post-marketing surveillance. No serious adverse events and no significant prolongation in the QT interval were reported. The information collected in the post-marketing surveillance is consistent with that reported in clinical trials.
Storage
Store below 30 °C in a dry place, protected from light. Keep out of reach of children.
